vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and REV Group, Inc. (REVG). Click either name above to swap in a different company.

REV Group, Inc. is the larger business by last-quarter revenue ($664.4M vs $156.4M, roughly 4.2× BIOCRYST PHARMACEUTICALS INC). On growth, REV Group, Inc. posted the faster year-over-year revenue change (11.1% vs 7.5%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 6.5%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Rev is an American speech-to-text company that provides closed captioning, subtitles, and transcription services. The company, based in San Francisco and Austin, was founded in 2010. PC Magazine named the service an "Editor's Choice" in 2018, and ranked it as the best transcription service of 2019.

BCRX vs REVG — Head-to-Head

Bigger by revenue
REVG
REVG
4.2× larger
REVG
$664.4M
$156.4M
BCRX
Growing faster (revenue YoY)
REVG
REVG
+3.6% gap
REVG
11.1%
7.5%
BCRX
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
6.5%
REVG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCRX
BCRX
REVG
REVG
Revenue
$156.4M
$664.4M
Net Profit
$28.9M
Gross Margin
15.4%
Operating Margin
13.6%
7.1%
Net Margin
4.3%
Revenue YoY
7.5%
11.1%
Net Profit YoY
-30.7%
EPS (diluted)
$0.00
$0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
REVG
REVG
Q1 26
$156.4M
Q4 25
$406.6M
$664.4M
Q3 25
$159.4M
$644.9M
Q2 25
$163.4M
$629.1M
Q1 25
$145.5M
$525.1M
Q4 24
$131.5M
$597.9M
Q3 24
$117.1M
$579.4M
Q2 24
$109.3M
$616.9M
Net Profit
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
$245.8M
$28.9M
Q3 25
$12.9M
$29.1M
Q2 25
$5.1M
$19.0M
Q1 25
$32.0K
$18.2M
Q4 24
$-26.8M
$41.7M
Q3 24
$-14.0M
$18.0M
Q2 24
$-12.7M
$15.2M
Gross Margin
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
97.7%
15.4%
Q3 25
98.6%
15.8%
Q2 25
98.3%
15.2%
Q1 25
96.9%
13.3%
Q4 24
95.4%
13.2%
Q3 24
97.3%
13.5%
Q2 24
98.4%
12.5%
Operating Margin
BCRX
BCRX
REVG
REVG
Q1 26
13.6%
Q4 25
64.0%
7.1%
Q3 25
18.6%
8.8%
Q2 25
18.2%
7.9%
Q1 25
14.6%
5.3%
Q4 24
-3.4%
5.8%
Q3 24
6.6%
4.9%
Q2 24
8.0%
3.7%
Net Margin
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
60.5%
4.3%
Q3 25
8.1%
4.5%
Q2 25
3.1%
3.0%
Q1 25
0.0%
3.5%
Q4 24
-20.4%
7.0%
Q3 24
-12.0%
3.1%
Q2 24
-11.6%
2.5%
EPS (diluted)
BCRX
BCRX
REVG
REVG
Q1 26
$0.00
Q4 25
$1.13
$0.57
Q3 25
$0.06
$0.59
Q2 25
$0.02
$0.38
Q1 25
$0.00
$0.35
Q4 24
$-0.13
$1.03
Q3 24
$-0.07
$0.35
Q2 24
$-0.06
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
REVG
REVG
Cash + ST InvestmentsLiquidity on hand
$259.0M
$34.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.3M
Total Assets
$465.1M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
REVG
REVG
Q1 26
$259.0M
Q4 25
$274.7M
$34.7M
Q3 25
$212.9M
$36.0M
Q2 25
$260.0M
$28.8M
Q1 25
$295.1M
$31.6M
Q4 24
$320.9M
$24.6M
Q3 24
$96.8M
$50.5M
Q2 24
$78.4M
$38.2M
Stockholders' Equity
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
$-119.2M
$416.3M
Q3 25
$-387.9M
$387.3M
Q2 25
$-421.6M
$357.8M
Q1 25
$-451.9M
$428.8M
Q4 24
$-475.9M
$435.1M
Q3 24
$-468.6M
$394.6M
Q2 24
$-475.6M
$379.7M
Total Assets
BCRX
BCRX
REVG
REVG
Q1 26
$465.1M
Q4 25
$514.2M
$1.2B
Q3 25
$446.4M
$1.2B
Q2 25
$457.2M
$1.2B
Q1 25
$480.0M
$1.2B
Q4 24
$490.4M
$1.2B
Q3 24
$491.3M
$1.3B
Q2 24
$472.4M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
REVG
REVG
Operating Cash FlowLast quarter
$76.9M
Free Cash FlowOCF − Capex
$53.7M
FCF MarginFCF / Revenue
8.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
2.66×
TTM Free Cash FlowTrailing 4 quarters
$190.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
$292.0M
$76.9M
Q3 25
$41.6M
$60.3M
Q2 25
$41.3M
$117.0M
Q1 25
$-27.5M
$-13.1M
Q4 24
$-5.2M
$68.6M
Q3 24
$8.2M
$14.4M
Q2 24
$-1.4M
$40.1M
Free Cash Flow
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
$291.2M
$53.7M
Q3 25
$40.3M
$48.7M
Q2 25
$41.1M
$105.6M
Q1 25
$-27.7M
$-18.0M
Q4 24
$-5.9M
$63.3M
Q3 24
$8.2M
$8.5M
Q2 24
$-1.5M
$34.2M
FCF Margin
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
71.6%
8.1%
Q3 25
25.3%
7.6%
Q2 25
25.2%
16.8%
Q1 25
-19.0%
-3.4%
Q4 24
-4.5%
10.6%
Q3 24
7.0%
1.5%
Q2 24
-1.4%
5.5%
Capex Intensity
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
0.2%
3.5%
Q3 25
0.8%
1.8%
Q2 25
0.1%
1.8%
Q1 25
0.1%
0.9%
Q4 24
0.5%
0.9%
Q3 24
0.1%
1.0%
Q2 24
0.1%
1.0%
Cash Conversion
BCRX
BCRX
REVG
REVG
Q1 26
Q4 25
1.19×
2.66×
Q3 25
3.23×
2.07×
Q2 25
8.12×
6.16×
Q1 25
-859.91×
-0.72×
Q4 24
1.65×
Q3 24
0.80×
Q2 24
2.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

REVG
REVG

Specialty Vehicles$507.4M76%
Recreational Vehicles$157.2M24%

Related Comparisons